Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Alirocumab · Praluent, REGN-727

Monoclonal antibody · Inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) · developed by Regeneron Pharmaceuticals

Approved FDA, Jul 2015
REGN Developer

What is Alirocumab?

Alirocumab is a human monoclonal antibody that binds PCSK9, preventing PCSK9 from binding LDL receptors on liver cells. This keeps more LDL receptors available to clear LDL cholesterol from the blood. It is studied in hypercholesterolemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Praluent, REGN-727, SAR-236553
Drug type
Monoclonal antibody
Targets
proprotein convertase subtilisin/kexin type 9 (PCSK9), low-density lipoprotein receptor (LDLR) (binding partner it blocks)
Mechanism
Inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9)
Pathways
LDL receptor degradation in hepatocytes, LDL cholesterol clearance
Therapy area
Metabolic
Developer
Regeneron Pharmaceuticals (REGN)
FDA status
Approved as Praluent (July 24, 2015), BLA125559 · FDA label
UNII
PP0SHH6V16

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 16, 2026). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Hypercholesterolemia

Other drugs acting on PCSK9

More from Regeneron Pharmaceuticals

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the REGN page.

Follow REGN, the company behind Alirocumab

See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

REGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.